The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Open accessAbstract
Background: Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult‐to‐treat patient population. Methods: Following a run‐in phase, patients (12–75 years) inadequately controlled despite therapy with high‐dose inhaled corticosteroids (ICS) and long‐acting β2‐agonists (LABA) with reduced lung function and a recent history of clinically significant exacerbations were randomized to receive omalizumab or placebo for 28 weeks in a double‐blind, parallel‐group, multicentre study. Results: A total of 419 patients were included in the efficacy analyses. The clinically significant asthma exacerbation rate (primary efficacy variable), adjusted for an observed relevant imbalance in history of clinically significant asthma exacerbations, was 0.68 with omalizumab and 0.91 with placebo (26% reduction) during the 28‐week treatment phase (P = 0.042). Without adjustment, a similar magnitude of effect was seen (19% reduction), but this did not reach statistical significance. Omalizumab significantly reduced severe asthma exacerbation rate (0.24 vs 0.48, P = 0.002) and emergency visit rate (0.24 vs 0.43, P = 0.038). Omalizumab significantly improved asthma‐related quality of life, morning peak expiratory flow and asthma symptom scores. The incidence of adverse events was similar between treatment groups. Conclusions: In patients with inadequately controlled severe persistent asthma, despite high‐dose ICS and LABA therapy, and often additional therapy, omalizumab significantly reduced the rate of clinically significant asthma exacerbations, severe exacerbations and emergency visits. Omalizumab is effective and should be considered as add‐on therapy for patients with inadequately controlled severe persistent asthma who have a significant unmet need despite best available therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Juniper, E. F., Guyatt, G. H., Epstein, R. S., Ferrie, P. J., Jaeschke, R., & Hiller, T. K. (1992) · Thorax · doi:10.1136/thx.47.2.76 · Cited by 1,232
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.6.ats9-00 · Cited by 909
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Self-citationThe ENFUMOSA Study Group (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00261903 · Cited by 759
Holgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1916.x · Cited by 522
Self-citationBarnes, P., Jonsson, B., & Klim, J. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09040636 · Cited by 434
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.
Suissa, S., Ernst, P., Boivin, J. F., Horwitz, R. I., Habbick, B., Cockroft, D., Blais, L., McNutt, M., Buist, A. S., & Spitzer, W. O. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.3.8118625 · Cited by 422
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Self-citation
Cited by
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Self-citationInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
Self-citationReddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
Brożek, J. L., Bousquet, J., Baena-Cagnani, C. E., Bonini, S., Canonica, G. W., Casale, T. B., van Wijk, R. G., Ohta, K., Zuberbier, T., & Schünemann, H. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.047 · Cited by 1,813
Self-citation
Metadata
- Authors
- Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., Fox, H., Blogg, M., & Surrey, K.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2004-12-20
- Volume
- 60
- Issue
- 3
- Pages
- 309-316
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2029587541
- Cited by
- 1,123
- References
- 31
- FWCI
- 24.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. https://app.cochat.ai/papers/10.1111/j.1398-9995.2004.00772.x
- The paper
- Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., Fox, H., Blogg, M., & Surrey, K. (2005). Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. https://doi.org/10.1111/j.1398-9995.2004.00772.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
